Vitamin D Therapy Market - Growth, Trends, and Forecast (2020 - 2025)
|出版商||Mordor Intelligence LLP||商品編碼||921930|
|出版日期||內容資訊||英文 115 Pages
|全球維他命D療法市場:成長，趨勢，及預測 Vitamin D Therapy Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日期: 2020年01月01日||內容資訊: 英文 115 Pages||
The Vitamin D Therapy Market studied was anticipated to grow with a CAGR of nearly 11.8% during the forecast period. The major factors attributing to the growth of the market are the presence of a huge patient pool due to lack of time with sedentary lifestyles along with the rapid growth of the aging population. Also, an increased prevalence of malnutrition cases such as osteoporosis and rickets among all the age groups in recent years has escalated the awareness programs and healthcare expenditure by the government authorities across the globe. For instance, according to the (CDC) Centers for Disease Control and Prevention report, in 2018, about USD 3.65 trillions of national health care expenditure was incurred by the United States which is expected to increase throughout the forecast period providing better opportunities to the research activities and manufacturers driving the global vitamin D therapy market.
Vitamin D is a group of fat-soluble secosteroids that are present only in few foods that are essential for the intestinal absorption of calcium, phosphate, and magnesium. When the skin is exposed to sunlight, it activates the synthesis of vitamin D from cholesterol. Among the vitamin D compounds, Vitamin D2 /ergocalciferol and vitamin D3 /cholecalciferol are considered to be essential for humans. The deficiency of these essential vitamins has been one of the most common problems in the past few years due to sedentary lifestyles leading to lesser exposure to sun resultant skin diseases, muscle weakness and bone pain driving the market.
Oral Route Of Administration is Expected to Hold the Major Market Share in the Vitamin D Therapy Market
North America Dominates the Market and Expected to do Same in the Forecast Period.
North America is expected to dominate the overall vitamin D therapy market throughout the forecast period. This dominance is mainly owing to the presence of leading players based in the United States, focus on research activities to develop more patient compliant products with enhanced efficiency coupled by the government support and increasing healthcare expenditure contributing to its outstanding market revenue share in the global vitamin D therapy market growth. Europe accounts for the second-largest share in the market which is attributed to its increased preference for the nutritional supplements due to enhanced healthcare awareness.
Regionally, the Asia Pacific market is anticipated to witness the highest CAGR in the overall vitamin D therapy market during the forecast period. The significant growth in the region can be attributed to sedentary lifestyles, huge target patient pool due to heavy population in developing nations like India, China and along with higher air pollution. Also, a rise in awareness programs about vitamin D deficiency by the government and manufacturers of emerging economies in the region is expected to boost the growth of the market propelling the global market revenue.
The global Vitamin D therapy market is moderately competitive and consists of several major players. Some prominent players that are currently dominating the market In terms of market share are acquiring the products, entering into partnerships with the other companies to consolidate their market positions across the globe and while others are distributing products. For instance, in June 2018, GlaxoSmithKline completed the buyout of Novartis' 36.5% stake in its Consumer Healthcare Joint Venture. Also, GSK completed a transaction with Pfizer in August 2019 to combine their consumer healthcare businesses and form a new world-leading Consumer Healthcare Joint Venture. The joint venture offers a range of products in vitamin and mineral supplements, among others which fuel the market growth. Some of the companies which are currently dominating the market are Pfizer Inc, Abbott Laboratories, GlaxoSmithKline PLC, Biotics Research Corporation, and Ortho Molecular Products Inc.